Last reviewed · How we verify
NCT04968223: SPIRIT
Neural Correlates of Social Touch and Interoceptive Perception As Potential Biomarker for Impaired Social Functioning
trial in Schizophrenia in 106 participants. Completed in 30 November 2024.
15 May 2024
Quick facts
| Lead sponsor | University of Oldenburg |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 106 |
| Start date | 16 August 2021 |
| Primary completion | 15 May 2024 |
| Estimated completion | 30 November 2024 |
| Sites | 1 location across Germany |
Conditions studied
- Schizophrenia — all drugs for Schizophrenia →
Sponsor
University of Oldenburg
Who can join
Adults 18 to 65, any sex, with Schizophrenia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Recent studies have shown that certain biomarkers of schizophrenia could help to better assess the individual course of the disease and thus, contribute to more personalized treatment options. The aim of the SPIRIT study is to identify potential biomarkers for the prediction of disease-associated outcomes by investigating the neurobiological mechanisms of underlying schizophrenia-related dysfunctions.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
Verify or expand the search:
- PubMed search for NCT04968223
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Schizophrenia
Currently open trials in the same condition.
- NCT07424404 — A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Au · Phase 3 · recruiting
- NCT07467993 — Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia · Phase 2 · recruiting
- NCT07379827 — Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT) · recruiting
- NCT06758414 — CBT-CP for Veterans With SMI · NA · recruiting
- NCT07395206 — Acceptability, Feasibility and Preliminary Outcomes of the Kiso Mind App for Outpatients With Schizophrenia Spectrum Dis · NA · recruiting
Other University of Oldenburg trials
Trials by the same sponsor.
- NCT06652828 — Perturbation-Based Treadmill Training to Prevent Unrecovered Falls in Geriatric Patients · NA · recruiting
- NCT06525805 — Readers' Attention of Shorter Versus Longer Abstracts of Systematic Reviews · NA · completed
- NCT04832750 — Depression-Reduction by Accelerated Personalized NeuroModulation and Its Effects on Sleep · completed
- NCT04770038 — Social Integration During Psychiatric Inpatient Therapy as Predictor of Treatment Response · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04968223 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Oldenburg
- Last refreshed: 9 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04968223.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing